iTeos Therapeutics (NASDAQ: ITOS)
$10.57
(-3.8%)
-$0.42
Price as of April 24, 2024, 4:00 p.m. ET
iTeos Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
iTeos Therapeutics Company Info
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.
News & Analysis
Featured Article
Why iTeos Therapeutics Topped the Market Today
The stock is about to become a component of a high-profile index.
Eric Volkman | Jan 3, 2022
Featured Article
Why iTeos Therapeutics Stock Soared Today
The biotech struck a potential $2 billion deal with a pharmaceutical giant.
Joe Tenebruso | Jun 14, 2021
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.